ReviewHuman vaccines & immunotherapeutics2018
Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.
Review in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global, regional, and national burden of meningitis and its aetiologies, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.The Lancet. Neurology · 2023Pooled it
- Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region.BMC infectious diseases · 2021Pooled it
- Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children.Human vaccines & immunotherapeutics · 2023Trial
- Bacterial Meningitis Epidemiology in Burkina Faso and Niger-High-Risk Countries in the Meningitis Belt of Sub-Saharan Africa, 2015-2023.The Journal of infectious diseases · 2026Article
- Review
- Risk Factors and Prevalence of Meningococcal Colonisation of Children Attending Kindergarten in Northern Hungary.Microorganisms · 2026Article
- Meningococcal Outbreaks in Tertiary Education Settings in the United Kingdom: Lessons from the 2026 Kent Cluster for Surveillance, Vaccination Policy, and Institutional Preparedness in Sub-Saharan Africa-A Narrative Review.Infectious disease reports · 2026Review
- Disease burden of Streptococcus pneumoniae and Neisseria meningitidis meningitis in children and adolescents: A population-based study.Medicine · 2026Article
- Emergence of pneumococcal meningitis outbreak in Northern Togo in 2023, lessons learned and challenges.BMC public health · 2026Article
- Prevalence and Risk of Meningococcal Disease or Carriage During Mass Gatherings and Associated Travel: Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2025Review
- Estimating the historical impact of outbreak response immunisation programmes across 210 outbreaks in low and middle-income countries.BMJ global health · 2025Article
- The burden of common neurological disorders in Asia: insights from the Global Burden of Disease Study (1990-2021).Journal of neurology · 2025Article
- Hydrocephalus and Cerebral Small Vessel Disease in an Adult With Meningococcal Meningitis and Dilated Cardiomyopathy: A Fatal Outcome.Clinical case reports · 2025Article
- Impact of lactobacillus probiotics on vaccine response in diabetic rats: modulation of inflammatory cytokines.American journal of clinical and experimental immunology · 2025Article
- Analysis of the trends in burden of meningitis in China from 1990 to 2021, and projections until 2036.Frontiers in public health · 2025Article
- Development of a rapid, simple multiplex PCR-dipstick assay for the detection ofFrontiers in cellular and infection microbiology · 2025Article
- Monophosphoryl Lipid A-based Adjuvant to Promote the Immunogenicity of Multivalent Meningococcal Polysaccharide Conjugate Vaccines.ImmunoHorizons · 2024Article
- WHO Strategic Advisory Group of Experts on Immunization recommendations for use of a novel pentavalent meningococcal ACWXY vaccine: a critical step towards ending meningococcal epidemics in Africa.Journal of travel medicine · 2024Article
- A perspective on the novel pentavalent Men5CV (NmCV-5) meningitis vaccine and Nigeria's pioneering rollout campaign.Le infezioni in medicina · 2024Review
- Meningococcal A conjugate vaccine coverage in the meningitis belt of Africa from 2010 to 2021: a modelling study.EClinicalMedicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Africa historically has had the highest incidence of meningococcal disease with high endemic rates and periodic epidemics. The meningitis belt, a region of sub-Saharan Africa extending from Senegal to Ethiopia, has experienced large, devastating epidemics. However, dramatic shifts in the epidemiology of meningococcal disease have occurred recently. For instance, meningococcal capsular group A (NmA) epidemics in the meningitis belt have essentially been eliminated by use of conjugate vaccine. However, NmW epidemics have emerged and spread across the continent since 2000; NmX epidemics have occurred sporadically, and NmC recently emerged in Nigeria and Niger. Outside the meningitis belt, NmB predominates in North Africa, while NmW followed by NmB predominate in South Africa. Improved surveillance is necessary to address the challenges of this changing epidemiologic picture. A low-cost, multivalent conjugate vaccine covering NmA and the emergent and prevalent meningococcal capsular groups C, W, and X in the meningitis belt is a pressing need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.